Daratumumab is the first in-class monoclonal anti-CD38 immunoglobulin G1 antibody with proven antimyeloma activity in both monotherapy and in combination with drugs such as lenalidomide and bortezomib.1 It has a favorable safety profile with typical adverse events such as upper respiratory tract symptoms at first infusion and later immunosuppressive effects.2
Rasmussen PK, Kiilgaard JF, Salomo M. Association of Choroidal Effusion and Infusion of Daratumumab. JAMA Ophthalmol. 2019;137(7):853–854. doi:10.1001/jamaophthalmol.2019.1427
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: